Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective of this study is to estimate the incidence of ocular adverse events (AEs) in patients with CNV secondary to AMD who are treated with 0.3 and/or 0.5 mg intravitreal ranibizumab.
Inclusion criteria
- Male and female patients ≥50 years of age with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)